In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with ...
Pre-Market: 5:02:04 a.m. EST Loading Chart for MRSN ...
Roche Holding AG Akt-0.56% CHF240.64B ...
Dyne Therapeutics Inc.-5.60% $1.56B ...
After hours: February 10 at 5:00:28 PM EST Loading Chart for GDTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback